Marcela V. Maus

Massachusetts General Hospital — United States

Medicine · Health Sciences

83h-index31.9kcitations505works7.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(417), Virus-based gene therapy research(76), Immune Cell Function and Interaction(73), Nanowire Synthesis and Applications(63), Viral Infectious Diseases and Gene Expression in Insects(44)

Publications503 total

Patterns, risk factors and management of CD19-directed chimeric antigen receptor T-cell therapy failure in CNS lymphoma
Journal of Hematology & Oncology·2026Open Access
Fanning the flames: IFN-γ fuels CAR-T inflammation and cytopenia
Journal of Clinical Investigation·2026Open Access
Drug-tolerant persisters and immunotherapy persister cells exhibit cross-resistance and share common survival mechanisms
Cell Death and Differentiation·2025
Prognostic value of serological and PET/CT response kinetics in patients with multiple myeloma treated with BCMA CAR-T
Leukemia·2025Open Access
Tuning CAR-T cells by targeting cancer-associated glycan in pancreatic cancer
Nature Communications·2025Open Access
Data from Cancer in 2025
2025Open Access
Cancer in 2025
Cancer Discovery·2025· 1 cited
Group Authors List 1 from Cancer in 2025
2025Open Access
Affinity-matured CD72-targeting nanobody CAR T cells enhance elimination of antigen-low B-cell malignancies
Journal for ImmunoTherapy of Cancer·2025Open Access
Granzyme B PET Imaging Enables Detection of CAR T-Cell Therapy Response in a Human Melanoma Mouse Model
Diagnostics·2025Open Access
Isolated oral CAR+ T cell lymphoma after tisagenlecleucel
Molecular Therapy·2025· 1 citedOpen Access
The Global State of Blood Cancers: An Ongoing Challenge
Blood Cancer Discovery·2025
Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
Clinical Cancer Research·2025Open Access
Validation and refinement of the new high-risk multiple myeloma (HRMM) criteria in relapsed or refractory patients treated with BCMA CAR-T.
Blood·2025Open Access
Triple base-edited dual targeting CD70/33 CAR T cells to avoid cytokine-mediated resistance in Acute Myeloid Leukemia
Blood·2025
Single-cell transcriptomics reveal mechanisms of efficacy and toxicity in anti-BCMA CAR-T cell therapies for multiple myeloma
Blood·2025
First-in-human phase 1 trial of trimeric APRIL (TriPRIL) CAR T cells in relapsed or refractory multiple myeloma: Clinical outcomes and biological correlates of disease response and resistance
Blood·2025Open Access
The efficacy of cilta-cel after a prior BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma
Blood·2025
Risk score and survival outcomes for multiple myeloma patients with disease refractory to BCMA CAR-T.
Blood·2025
365 Single-cell transcriptional profiles of cilta-cel and ide-cel associate with response in multiple myeloma
Regular and Young Investigator Award Abstracts·2025Open Access
page 1 of 26Next →

Frequent Co-authors

Carl H. June(20), Matthew J. Frigault(11), Bruce L. Levine(9), Simon F. Lacey(7), Irene Scarfò(7), Joseph A. Fraietta(7), Mark B. Leick(7), Rebecca C. Larson(6), Andrea Schmidts(6), Stephan A. Grupp(5), J. Joseph Melenhorst(5), Michael Kalos(5), Yangbing Zhao(5), Sattva S. Neelapu(4), Gabriela Plesa(4), Ana P. Castaño(4), Bryan D. Choi(4), Amanda A. Bouffard(4), Stefanie R. Bailey(4), David L. Porter(4)